All Resources
Access a curated library of reports, policy submissions, data insights, and other materials informing Canada’s life sciences ecosystem.
Filter by
IMC Response to PMPRB 2020 Draft Guidelines
IMC critiques the June 2020 Federal Court decision that confidential third-party payments are ultra vires the Patent Act….
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure…
